Filtered By:
Therapy: Antiviral Therapy

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 305 results found since Jan 2013.

Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Biomed Pharmacother. 2021 Mar 16;138:111518. doi: 10.1016/j.biopha.2021.111518. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessit...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 28, 2021 Category: Drugs & Pharmacology Authors: Mona Sadat Mirtaleb Amir Hossein Mirtaleb Hassan Nosrati Jalal Heshmatnia Reza Falak Reza Zolfaghari Emameh Source Type: research

Molecules, Vol. 26, Pages 1775: Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2
as Valan Arasu Mohammad Iqbal Yatoo Ruchi Tiwari Kuldeep Dhama The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2), is the most important health issue, internationally. With no specific and effective antiviral therapy for COVID-19, new or repurposed antiviral are urgently needed. Phytochemicals pose a ray of hope for human health during this pandemic, and a great deal of research is concentrated on it. Phytochemicals have been used as antiviral agents against several viruses since they could inhibit several viruses via different mechanisms of d...
Source: Molecules - March 22, 2021 Category: Chemistry Authors: Arumugam Vijaya Anand Balasubramanian Balamuralikrishnan Mohandass Kaviya Kathirvel Bharathi Aluru Parithathvi Meyyazhagan Arun Nachiappan Senthilkumar Shanmugam Velayuthaprabhu Muthukrishnan Saradhadevi Naif Abdullah Al-Dhabi Mariadhas Valan Arasu Mohamm Tags: Review Source Type: research

Clinical and Therapeutic Approach to Hospitalized COVID-19 Patients: A Pediatric Cohort in Portugal
CONCLUSION: A significant proportion of our population presented severe and critical disease, was hospitalized and received treatment according to the most recent data, although most patients had mild disease. COVID-19 treatment in children is a clinical challenge and clinical trials are urgently needed.PMID:33715760 | DOI:10.20344/amp.15360
Source: Acta Medica Portuguesa - March 15, 2021 Category: General Medicine Authors: B árbara Martins Saraiva Ana Margarida Garcia Tiago Milheiro Silva Catarina Gouveia Maria Jo ão Brito Source Type: research

Serum cytokine levels of COVID-19 patients after 7  days of treatment with Favipiravir or Kaletra
CONCLUSION: Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment although CT, CRP and LDH suggest a decline in lung inflammation. There was limited evidence for a viral-mediated cytokine storm in these COVID-19 subjects.PMID:33631512 | PMC:PMC7826095 | DOI:10.1016/j.intimp.2021.107407
Source: International Immunopharmacology - February 25, 2021 Category: Allergy & Immunology Authors: Esmaeil Mortaz Ali Bassir Neda Dalil Roofchayee Neda K Dezfuli Hamidreza Jamaati Payam Tabarsi Afshin Moniri Mitra Rezaei Payam Mehrian Mohammad Varahram Majid Marjani Sharon Mumby Ian M Adcock Source Type: research

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial
CONCLUSIONS AND RELEVANCE: rSIFN-co was associated with a shorter time of clinical improvement than traditional interferon-alpha in the treatment of moderate-to-severe COVID-19 when combined with baseline antiviral agents. rSIFN-co therapy alone or combined with other antiviral therapy is worth to be further studied.Key messagesThere are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. Interferon alphas, by inducing both innate and adaptive immune responses, have shown clinical efficacy in treating severe acute respiratory syndrome coronavirus and Middle East respiratory sy...
Source: Annals of Medicine - February 23, 2021 Category: Internal Medicine Authors: Chuan Li Fengming Luo Chengwu Liu Nian Xiong Zhihua Xu Wei Zhang Ming Yang Ye Wang Dan Liu Chao Yu Jia Zeng Li Zhang Duo Li Yanbin Liu Mei Feng Ruoyang Liu Jiandong Mei Senyi Deng Zhen Zeng Yuanhong He Haiyan Liu Zhengyu Shi Meng Duan Deying Kang Jiayu Li Source Type: research

Comparison of acute pneumonia caused by SARS-COV-2 and other respiratory viruses in children: a retrospective multi-center cohort study during COVID-19 outbreak
ConclusionThe symptoms and severity of COVID-19 pneumonia in children were no more severe than those in children with other viral pneumonia. Lopinavir-ritonavir, ribavirin and arbidol do not shorten the duration of positive PCR results from pharyngeal swabs in children with COVID-19. During the COVID-19 outbreak, attention also must be given to children with infection by other pathogens infection.
Source: Military Medical Research - February 16, 2021 Category: International Medicine & Public Health Source Type: research

New combination antiviral therapy against coronavirus
(University of Malaga) SARS-CoV-2 genome is three times larger than influenza genome. Both consist of NRA molecules that mutate when replicate. It is essential to know its mutant spectrum, in other words, its 'fingerprints', to achieve an appropriate treatment that reduces its infectivity -the capacity of pathogens to invade organisms and cause infections-, since its composition of variants could determine how infection would develop in each patient.
Source: EurekAlert! - Medicine and Health - February 12, 2021 Category: International Medicine & Public Health Source Type: news

The three frontlines against COVID-19: Brain, Behavior, and Immunity.
Abstract The pandemic outbreak of coronavirus disease 2019 (COVID-19) is raising global anxiety and fear of both real and perceived health threat from the virus. Overwhelming evidence shows infected patients experiencing neuropsychiatric complications, suggesting that the "psychoneuroimmunity" model might be beneficial in understanding the impact of the virus. Therefore, this Special Issue on "Immunopsychiatry of COVID-19 Pandemic" was launched immediately after the pandemic was declared, with the first paper accepted on the March 25th, 2020. A total of ninety-three papers were accepted, the last one was on the Ju...
Source: Brain, Behavior, and Immunity - February 3, 2021 Category: Neurology Authors: Wang SC, Su KP, Pariante CM Tags: Brain Behav Immun Source Type: research

Efficacy of ribavirin and interferon- α therapy for hospitalized patients with COVID-19: a multicenter, retrospective cohort study
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 83.3 million patients with more than 1,831,000 deaths worldwide (WHO, 2021). This pandemic has brought a huge challenge to the global public health (WHO, 2020; Wu and McGoogan, 2020). However, except for the treatment experience of earlier strains of coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), there was insufficient evidence to support a specific antiviral therapy (Sanders et al., 2020).
Source: International Journal of Infectious Diseases - January 27, 2021 Category: Infectious Diseases Authors: Hui Li, Nian Xiong, Changjun Li, Yanhong Gong, Li Liu, Heping Yang, Xiangping Tan, Nan Jiang, Qiao Zong, Jing Wang, Zuxun Lu, Xiaoxv Yin Source Type: research

Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study
Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2; no specific effective medication to treat the disease has been identified to date. We aimed to investigate the administered medications and intervention times for patients who completely recovered from COVID-19. This single-center, retrospective, observational study included 55 patients with COVID-19 who were transferred to Shenyang Sixth People's Hospital between January 20 and March 15, 2020. Data on demographics, symptoms, laboratory indicators, treatment processes, and clinical outcomes were collecte...
Source: Medicine - January 15, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system
Publication date: Available online 12 January 2021Source: Antiviral ResearchAuthor(s): Qingyuan Zhu, Yaling Zhang, Li Wang, Xiangyu Yao, Daitze Wu, Junjun Cheng, Xiaoyu Pan, Haixia Liu, Zhipeng Yan, Lu Gao
Source: Antiviral Therapy - January 12, 2021 Category: Virology Source Type: research